lundi 16 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· November 24, 2025

Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting

View original at finance.yahoo.com
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients

    80% confidence
  • Lilly has been pioneering life-changing discoveries for nearly 150 years

    80% confidence
  • Pirtobrutinib is 300 times more selective for BTK versus 98% of other kinases tested in preclinical studies

    80% confidence
  • Jaypirca is the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor

    80% confidence
  • Continued approval for Jaypirca's MCL and CLL/SLL indications may be contingent upon verification and description of clinical benefit in a confirmatory trial

    80% confidence
  • Data from across the pirtobrutinib development program and investigator-led studies reinforce the medicine's unique clinical profile and its potential role across treatment settings and B-cell malignancies

    80% confidence
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting: Source | Via News | fr.via.news